Ricardo Fermo
Psychiatry · Charleston, SCNPI 1386752236
Payments from drug & device makers
Across 689 payments — averaging $380.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$114K
- AbbVie$78K
- Alkermes, Inc.$36K
- Corium, LLC$21K
- Johnson & Johnson$9K
- Eisai Inc.$2K
- plus $3K from 21 others
What the payments were for
- Consulting fees$67,94026%
- Speaking & faculty fees$170,75065%
- Travel & lodging$12,1595%
- Food & beverage$11,4554%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 125 | $113,897 |
| AbbVie(2 entities) | 294 | $78,431 |
| Alkermes, Inc. | 56 | $35,601 |
| Corium, LLC | 36 | $20,991 |
| Johnson & Johnson | 26 | $9,034 |
| Eisai Inc. | 2 | $1,500 |
| Otsuka America Pharmaceutical, Inc. | 13 | $354 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $312 |
| Sunovion Pharmaceuticals Inc. | 24 | $307 |
| Neos Therapeutics, LP | 9 | $220 |
| Ironshore Pharmaceuticals Inc. | 10 | $220 |
| Janssen Scientific Affairs, LLC | 3 | $217 |
| Lundbeck LLC | 26 | $210 |
| Vanda Pharmaceuticals Inc. | 6 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $190 |
| E.r. Squibb & Sons, L.L.C. | 7 | $163 |
| Supernus Pharmaceuticals, Inc. | 5 | $108 |
| Tris Pharma Inc | 5 | $106 |
| Jazz Pharmaceuticals Inc. | 5 | $74 |
| Neuronetics, Inc. | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Bausch Health US, LLC | 3 | $52 |
| Lilly USA, LLC | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$262,380 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 33 | $66,595 |
| FanaptIloperidone | 21 | $43,938 |
| TrintellixVortioxetine Hydrobromide | 25 | $20,919 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,079 |
| VyvanseLisdexamfetamine Dimesylate | 30 | $11,446 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 109 | $8,516 |
| Lisdexamfetamine Dimesylate | 31 | $5,422 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 164 | $4,837 |
| Aripiprazole | 28 | $2,320 |
| Dextroamphetamine Sulfate | 33 | $2,208 |
| Duloxetine Hcl | 70 | $2,125 |
| Lamotrigine | 133 | $2,093 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $1,289 |
| Alprazolam | 212 | $1,065 |
| Quetiapine Fumarate | 49 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $78,431 | $66,59533 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $191 | $43,93821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $190 | $32,36555 claims |
| Alkermes, Inc.Lybalvi | $35,601 | $18,07912 claims |
| Lilly USA, LLCOlanzapine | $27 | $30140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Charleston
- Jacobo MintzerCharleston$4.9M
- Eduardo CifuentesCharleston$675K
- Mark GeorgeCharleston$332K
- Thomas UhdeCharleston$205K
- Olga Brawman-MintzerCharleston$160K
- Jessica BroadwayCharleston$146K
- Floyd SalleeCharleston$121K
- Kathleen BradyCharleston$110K
- Constance GuilleCharleston$110K
- Robert MalcolmCharleston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.